Want to see DMAC full AI Analyst Report?
Top Page
Diamedica Therapeutics
(NASDAQ:DMAC)
Select Model
Select Model
Rating:55Neutral
Price Target:
$7.50
▲(9.49% Upside)
Action:Reiterated
Date:06/30/26
DMAC scores as mid-range primarily due to weak financial performance (no revenue and ongoing, widening losses with cash burn), partially offset by low leverage and a constructive earnings-call update showing clinical execution and a stated cash runway through 2027. Technicals are moderately positive, while valuation is constrained by ongoing losses and no dividend yield.
Positive Factors
Clinical momentum
Sustained, multicountry enrollment above 70% and an activated network of ~70 sites materially reduces execution risk and shortens time to an interim readout. A defined interim framework creates a clear binary milestone that can de‑risk the stroke program and inform go/no‑go decisions.
Negative Factors
No commercial revenue
Absence of product revenue means operations rely on financing rather than internal cash flow. Persistent, widening net losses translate directly into funding needs and investor dilution risk if clinical timelines slip or additional trials/resampling are required.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical momentum
Sustained, multicountry enrollment above 70% and an activated network of ~70 sites materially reduces execution risk and shortens time to an interim readout. A defined interim framework creates a clear binary milestone that can de‑risk the stroke program and inform go/no‑go decisions.
Read all positive factors
Diamedica Therapeutics (DMAC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$410.59M
Dividend YieldN/A
Average Volume (3M)173.70K
Price to Earnings (P/E)―
Beta (1Y)1.47
Revenue GrowthN/A
EPS Growth-9.22%
CountryUS
Employees27
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.71
Shares Outstanding53,883,347
10 Day Avg. Volume189,843
30 Day Avg. Volume173,699
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)6.66
Price to Sales (P/S)0.00
P/FCF Ratio-12.85
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.68
Forecast
1Y Price Target
$13.00Price Target Upside89.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.76
Revenue Forecast (FY)N/A
Diamedica Therapeutics Business Overview & Revenue Model
Company Description
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein...
How the Company Makes Money
Diamedica Therapeutics does not have publicly established, recurring commercial revenue from product sales because its programs are in clinical development and its lead candidate (DM199) is not approved for marketing. As a result, the company’s op...
Diamedica Therapeutics Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Positive
The call conveyed meaningful clinical progress (stroke enrollment >70%, encouraging Phase II efficacy signals, Health Canada approval and active preeclampsia cohorts) and a clear pathway to multiple near-term clinical milestones through 2027. Financially, the company maintains a runway into 2027 but reported a quarter-over-quarter decline in cash, higher quarterly cash burn and materially higher R&D spend. Regulatory uncertainty in the U.S. (additional preclinical testing and an adverse rabbit study result) represents the primary risk to U.S. trial timelines. On balance, the clinical momentum and regulatory/operational achievements outweigh the financial and preclinical challenges at this stage.Positive Updates
ReMEDy2 Stroke Trial Enrollment Surpassed 70%
Enrollment in the global ReMEDy2 acute ischemic stroke trial has surpassed 70% of the target required for the interim analysis; approximately 70 sites are activated across the U.S., Canada, U.K. and six additional European countries. Company reiterates intention to complete interim analysis by end of 2026.
Negative Updates
Quarterly Cash Decline and Working Capital Reduction
Cash and short-term investments decreased from $59.9M (Dec 31, 2025) to $51.3M (Mar 31, 2026), a ~14.4% decline quarter-over-quarter. Working capital declined from $55.5M to $46.6M (≈16.0% decrease).
Read all updates
Q1-2026 Updates
Positive
Negative
ReMEDy2 Stroke Trial Enrollment Surpassed 70%
Enrollment in the global ReMEDy2 acute ischemic stroke trial has surpassed 70% of the target required for the interim analysis; approximately 70 sites are activated across the U.S., Canada, U.K. and six additional European countries. Company reiterates intention to complete interim analysis by end of 2026.
Read all positive updates
Company Guidance
Management reiterated that as of March 31, 2026 DiaMedica had $51.3M in cash, cash equivalents and short‑term investments (down from $59.9M at 12/31/25), current liabilities of $5.7M and working capital of $46.6M, and expects this funding to be sufficient to support planned clinical studies and operations through 2027; Q1 2026 net cash used in operating activities was $9.1M (vs $7.1M Q1 2025), R&D expense was $8.0M (vs $5.7M) and G&A was $2.5M, with R&D expected to moderately increase and G&A to remain relatively consistent. On the clinical side, ReMEDy2 stroke enrollment has surpassed 70% with ~70 sites activated across the U.S., Canada, U.K. and six additional European countries, management reiterated an interim analysis target by the end of 2026 (futility review or a re‑sample to ~300–700 patients; interim triggered after ~200 patients with a 90‑day primary endpoint plus ~4 weeks for analysis), and full enrollment could be completed in Q1 2027 if a positive effect is observed. For preeclampsia, the Part 1a extension cohort (12 patients, cohort 10) is near completion with a data update expected later this quarter, Part 1b and Part 2 will each enroll up to 30 patients (three doses to be evaluated; announced dosing 5/10/15 µg/kg SC every 3 days until delivery), the global Phase II early‑onset trial has Health Canada approval with Canadian enrollment planned by year‑end and a U.K. CTA filing this quarter, and the first patient in the fetal growth restriction IST cohort is expected this quarter; finally, the FDA requested additional embryo/fetal development data after a rabbit study issue and DiaMedica has proposed a rat study that, if accepted, would take roughly 3–4 months to complete.Diamedica Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -35.03M | -32.70M | -24.38M | -19.31M | -13.62M | -13.54M |
| Net Income | -35.10M | -32.77M | -24.44M | -19.38M | -13.68M | -13.59M |
Balance Sheet | ||||||
| Total Assets | 53.08M | 61.37M | 46.34M | 54.16M | 34.40M | 45.55M |
| Cash, Cash Equivalents and Short-Term Investments | 51.33M | 59.89M | 44.15M | 52.90M | 33.50M | 45.11M |
| Total Debt | 212.00K | 240.00K | 340.00K | 400.00K | 469.00K | 52.00K |
| Total Liabilities | 5.84M | 5.26M | 5.63M | 3.10M | 2.57M | 1.53M |
| Stockholders Equity | 47.23M | 56.11M | 40.72M | 51.06M | 31.83M | 44.02M |
Cash Flow | ||||||
| Free Cash Flow | -31.09M | -29.10M | -22.10M | -18.75M | -11.59M | -12.27M |
| Operating Cash Flow | -31.05M | -29.06M | -22.08M | -18.73M | -11.51M | -12.25M |
| Investing Cash Flow | -11.37M | -2.19M | 8.56M | -18.30M | 11.54M | -20.54M |
| Financing Cash Flow | 44.68M | 43.88M | 11.99M | 36.84M | -6.00K | 30.09M |
Diamedica Therapeutics Technical Analysis
Positive
6.85
Price Trends
6.11
Positive
6.74
Positive
7.17
Positive
Market Momentum
0.35
Negative
73.91
Negative
88.33
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DMAC, the sentiment is Positive. The current price of 6.85 is above the 20-day moving average (MA) of 6.12, above the 50-day MA of 6.11, and below the 200-day MA of 7.17, indicating a bullish trend. The MACD of 0.35 indicates Negative momentum. The RSI at 73.91 is Negative, neither overbought nor oversold. The STOCH value of 88.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DMAC.
Diamedica Therapeutics Risk Analysis
Diamedica Therapeutics disclosed 61 risk factors in its most recent earnings report. Diamedica Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Diamedica Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $1.34B | -10.00 | -59.27% | ― | -100.00% | -62.96% | |
55 Neutral | $410.59M | -10.73 | -77.09% | ― | ― | -9.22% | |
52 Neutral | $419.30M | -2.05 | -70.79% | ― | ― | 28.56% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $18.95M | -1.27 | -64.17% | ― | -100.00% | 94.65% | |
44 Neutral | $454.16M | -11.91 | -34.82% | ― | ― | 41.21% | |
44 Neutral | $894.58M | -4.48 | -101.19% | ― | ― | -3.74% |
* Healthcare Sector Average
DMAC
Diamedica Therapeutics
7.62
3.99
109.92%
TVRD
Tvardi Therapeutics
2.02
-20.44
-91.01%
CAPR
Capricor Therapeutics
23.21
12.96
126.44%
RCKT
Rocket Pharmaceuticals
3.84
0.94
32.41%
BNTC
Benitec Biopharma
13.22
0.05
0.38%
ANNX
Annexon Biosciences
5.46
2.73
100.00%
Diamedica Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
DiaMedica Shareholders Approve Governance, Compensation and Incentive Plan
Positive
May 21, 2026
DiaMedica Therapeutics Inc. held its 2026 Annual General Meeting of Shareholders on May 20, 2026, where investors re-elected seven incumbent directors to the board and reaffirmed the company’s governance continuity. Shareholders also ratifie...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.